New migraine pill NB001 put to the test in phase 2 trial
NCT ID NCT07577050
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a new drug called NB001 can quickly stop migraine pain and other bothersome symptoms. About 120 adults with migraines will take different doses of NB001 or a placebo at the start of an attack. Researchers will check if pain and symptoms go away within 2 hours.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NB001
- What this could lead to
- If successful, NB001 could offer a new fast-acting option to stop migraine pain and bothersome symptoms within 2 hours.
- What could go wrong
- This is an early Phase 2 trial with only 120 people, so results may not apply to everyone. It is also placebo-controlled, meaning the drug might not work better than a dummy pill.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIGRAINE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a numbing nose treatment stop migraine pain in its tracks?
- Can migraine meds be safe while breastfeeding? a new study investigates
- Could a symptom registry unmask hidden migraine variants?
- A migraine-blocking antibody tested in children as young as 6
- Mind over migraine: brain network may explain why some expect side effects
- The eyes as a window to the brain: can a simple scan monitor MS, Alzheimer's, and Parkinson's?